Working… Menu

Safety of Nasal Influenza Immunisation in Children With Asthma (SNIFFLE-4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02866942
Recruitment Status : Completed
First Posted : August 15, 2016
Results First Posted : April 26, 2019
Last Update Posted : May 10, 2019
Public Health England
Information provided by (Responsible Party):
Paul Turner, Imperial College London

Brief Summary:

A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine) has recently been approved by a number of licensing boards and is given by a spray into the nose. In the United Kingdom (UK), the vaccine has been demonstrated to be highly effective against influenza infection. Further, despite concerns that LAIV can cause wheezing in children under age 2 years, the previous SNIFFLE studies have demonstrated it to be safe in children over 2 years with mild-moderate asthma.

The objective of this multicentre study is to further assess the safety of intranasal LAIV in children with asthma and recurrent wheeze, including those with severe symptoms.

Condition or disease Intervention/treatment Phase
Asthma Drug: Administration of Live attenuated influenza vaccine (LAIV) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 479 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Safety of Nasal Influenza Immunisation in Children With Asthma - The SNIFFLE-4 Study
Actual Study Start Date : October 2016
Actual Primary Completion Date : March 2017
Actual Study Completion Date : March 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma Flu Flu Shot

Arm Intervention/treatment
Experimental: Asthma
LAIV administration in children with asthma receiving treatment according to British Thoracic Society step 2+
Drug: Administration of Live attenuated influenza vaccine (LAIV)
Other Names:
  • Flumist
  • Fluenz

Primary Outcome Measures :
  1. Change in Asthma Symptoms and Control Pre and 4 Weeks Post LAIV, as Assessed by Validated Questionnaire [ Time Frame: 4 weeks post LAIV ]

    The validated questionnaire to be used will depend on the age of the enrolled child:

    • Age 2-4 years: TRACK questionnaire
    • Age 5-11 years: Children's Asthma Control Test (C-ACT) score
    • Age 12+ years: Asthma Control Test (ACT) score

    The change in score (using the appropriate questionnaire for age) between pre- and 4 weeks post LAIV will be used to assess the primary outcome across all participants. a change in (c-)ACT of at least 3 points, or 10 points for TRACK will be determined a significant change.

    For TRACK, the minimum and maximum score possible is 0 and 100 respectively, the higher the score, the better is symptom control.

    For c-ACT, the minimum and maximum score possible is 0 and 27 respectively, the higher the score, the better controlled are asthma symptoms.

    For ACT, the minimum and maximum score possible is 5 and 25 respectively, the higher the score, the better controlled are asthma symptoms.

Secondary Outcome Measures :
  1. Incidence of Adverse Events (AE) and Serious Adverse Events (SAEs) in Children Receiving LAIV [ Time Frame: Up to 4 weeks post LAIV administration ]

    Incidence of a 'significant exacerbation' in asthma, defined as:

    i. At least 3 day course of oral steroids following an unscheduled contact with a healthcare professional; OR ii. Unscheduled visit to an Emergency department or admission to hospital for treatment of asthma symptoms, requiring systemic corticosteroids

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 2 - 18 years old (inclusive)
  • Physician diagnosis of asthma or recurrent wheezing (by the hospital specialist) AND (i) in children age 2-4 years: ≥2 exacerbations in the past year requiring oral steroids or observation in-hospital beyond 4 hours duration, OR (ii) in children ≥ 5 years of age, receiving treatment equivalent to at least BTS/SIGN step 2 therapy.
  • Written informed consent from parent/guardian (or the patient themselves from age 16 years), with assent from children aged 8 years and above wherever possible.

Exclusion Criteria:

  1. Admission to Paediatric Intensive Care for invasive ventilation due to a respiratory illness in the preceding 2 years.
  2. Contraindications to LAIV (notwithstanding allergy to egg protein), which include:

    1. Hypersensitivity to the active ingredients, gelatin or gentamicin (a possible trace residue)
    2. Previous systemic allergic reaction to LAIV
    3. Previous allergic reaction to an influenza vaccine (not LAIV) is a relative contra-indication, which must be discussed with the site PI to confirm patient suitability
    4. Children/adolescents who are clinically immunodeficient due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids**.

      **High-dose steroids is defined as a treatment course for at least one month, equivalent to a dose greater than 20mg prednisolone per day (any age), or for children under 20kg, a dose greater than 1mg/kg/day.

      NB: LAIV is not contraindicated for use in individuals with asymptomatic HIV infection; or individuals who are receiving topical/inhaled/low-dose oral systemic corticosteroids or those receiving corticosteroids as replacement therapy, e.g. for adrenal insufficiency.

    5. Children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection.
    6. pregnancy
  3. Contraindications to vaccination on that occasion, e.g. due to child being acutely unwell:

    1. Febrile ≥38.0 degrees C in last 72 hours
    2. *Acute wheeze in last 72 hours requiring treatment beyond that normally prescribed for regular use by the child's treating healthcare professional
    3. *Recent admission to hospital in last 2 weeks for acute asthma
    4. *Current oral steroid for asthma exacerbation or course completed within last 2 weeks
    5. Any other significant condition or circumstance which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

      • Items 3b-3d are relative contra-indications: Many children with "difficult-to-control" symptoms may meet fail to meet these criteria on a routine basis. Where these are present, the study centre PIs are able to authorise participation on a case-by-case basis, after assessing the child and their lung function at the time of enrolment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02866942

Sponsors and Collaborators
Imperial College London
Public Health England
Layout table for investigator information
Principal Investigator: Paul J Turner Imperial College London / Imperial College Healthcare NHS Trust / Public Health England
  Study Documents (Full-Text)

Documents provided by Paul Turner, Imperial College London:

Layout table for additonal information
Responsible Party: Paul Turner, MRC Clinician Scientist, Imperial College London Identifier: NCT02866942     History of Changes
Other Study ID Numbers: 16SM3348
2016-002352-24 ( EudraCT Number )
First Posted: August 15, 2016    Key Record Dates
Results First Posted: April 26, 2019
Last Update Posted: May 10, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs